Skip to Content


Morton Grove Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 21 Abbreviated New Drug Applications

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 65986


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA or Agency) is withdrawing approval of 21 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.


Approval is withdrawn as of January 2, 2020.

Start Further Info


Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, SUPPLEMENTARY INFORMATION: The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

Application No.DrugApplicant
ANDA 040759Phenytoin Sodium Capsules, 30milligrams (mg) (Extended)Morton Grove Pharmaceuticals, Inc., 6451 Main St., Morton Grove, IL 60053.
ANDA 062349Nystatin Oral Suspension, 100,000 units/milliters (mL)G&W Laboratories, Inc., 301 Helen St., South Plainfield, NJ 07080.
ANDA 062483Griseofulvin V (griseofulvin microsize) Oral Suspension, 125 mg/5 mLValeant Pharmaceuticals North America, LLC, 400 Somerset Corporate Blvd., Bridgewater, NJ 08807.
ANDA 063264Amikacin Sulfate Injection USP, Equivalent to (EQ) 250 mg base/mLHospira, Inc., 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.
ANDA 072655Amantadine Hydrochloride (HCl) Syrup USP, 50 mg/5 mLG&W Laboratories, Inc.
ANDA 074176Cimetidine HCl Oral Solution, EQ 300 mg base/5 mLDo.
ANDA 075366Sotalol HCl Tablets USP 80 mg, 120 mg, 160 mg, and 240 mgUpsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369.
ANDA 075887Fluvoxamine Maleate Tablets, 25 mg, 50 mg, and 100 mgDo.
ANDA 076709Fentanyl Extended-Release Film, 25 micrograms (mcg)/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hrActavis Laboratories UT, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc, 577 Chipeta Way, Salt Lake City, UT 84108.
ANDA 076841Mesalamine Enema, 4 grams (gm)/60 mLG&W Laboratories, Inc.
ANDA 077062Fentanyl Extended-Release Film, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, and 100 mcg/hrMayne Pharma LLC, 1240 Sugg Parkway, Greenville, NC 27834.
ANDA 078426Zolpidem Tartrate Tablets, 5 mg and 10 mgMorton Grove Pharmaceuticals Inc.
ANDA 078653Ranitidine HCl Tablets USP, EQ 150 mg baseDo.
ANDA 078701Ranitidine HCl Tablets USP, EQ 150 mg base and EQ 300 mg baseDo.
ANDA 078884Ranitidine HCl Tablets USP, EQ 75 mg baseDo.
ANDA 087811Phrenilin (acetaminophen and butalbital) Tablets, 325 mg/50 mgBausch Health US, LLC.
ANDA 088761Prometh VC Plain (promethazine HCl and phenylephrine HCl) Syrup, 5 mg/5mL, and 6.25 mg/5 mLG&W Laboratories, Inc.
ANDA 088762Prometh w/Dextromethorphan (promethazine HCl and dextromethorphan hydrobromide) Syrup, 6.25 mg/5 mL and 15 mg/5 mLDo.
ANDA 090786Carbidopa, Entacapone, and Levodopa Tablets, 12.5 mg/200 mg/50 mgMorton Grove Pharmaceuticals Inc.
ANDA 091267Donepezil HCl Tablets, 5 mg and 10 mgDo.
ANDA 201947Morphine Sulfate Oral Solution, 10 mg/5 mL and 20 mg/5 mLVistaPharm, Inc., 7265 Ulmerton Rd., Largo, FL 33771.
Do = Ditto.

Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of January 2, 2020. Approval of each entire application is withdrawn, including any strengths or products inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on January 2, 2020 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Start Signature

Dated: November 25, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

End Signature End Further Info End Preamble

[FR Doc. 2019-25946 Filed 11-29-19; 8:45 am]